A5008557181- Estrogen and related hormone effects
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Computational Drug Discovery Methods
- Explainable Artificial Intelligence (XAI)
- Anomaly Detection Techniques and Applications
- Data Visualization and Analytics
- Synthesis and biological activity
- Cognitive Science and Education Research
- Fire Detection and Safety Systems
- Cytokine Signaling Pathways and Interactions
- Child Nutrition and Feeding Issues
- Spacecraft Design and Technology
- Fractal and DNA sequence analysis
- Advanced Statistical Methods and Models
- Statistical Distribution Estimation and Applications
- COVID-19 epidemiological studies
- Astro and Planetary Science
- Cancer therapeutics and mechanisms
- Teacher Professional Development and Motivation
- Mental Health Research Topics
- Competency Development and Evaluation
- School Choice and Performance
- Ovarian cancer diagnosis and treatment
- Higher Education and Employability
University of Toronto
2020-2023
Public Health Ontario
2020
Edison Pharmaceuticals (United States)
2014-2018
Pennsylvania State University
2017
Tracon Pharmaceuticals (United States)
2015
Louisiana State University
1987
Approximately 80% of breast cancers are estrogen receptor alpha (ER-α) positive, and although women typically initially respond well to antihormonal therapies such as tamoxifen aromatase inhibitors, resistance often emerges. Although a variety mechanism may be at play in this state, there is evidence that many cases the ER still plays central role, including mutations leading constitutively active receptor. Fulvestrant steroid-based, selective degrader (SERD) both antagonizes degrades ER-α...
ER-targeted therapeutics provide valuable treatment options for patients with ER+ breast cancer, however, current relapse and mortality rates emphasize the need improved therapeutic strategies. The recent discovery of prevalent ESR1 mutations in relapsed tumors underscores a sustained reliance advanced on ERα signaling, provides strong rationale continued targeting ERα. Here we describe GDC-0810, novel, non-steroidal, orally bioavailable selective ER downregulator (SERD), which was...
There are myriad ways to analyse a dataset. But which one trust? In the face of such uncertainty, analysts may adopt multiverse analysis: running all reasonable analyses on Yet this is cognitively and technically difficult with existing tools—how does specify execute combinations dataset?—and often requires discarding workflows. We present multiverse, tool for implementing in R expressive syntax supporting computational notebook supports building up through local changes single analysis...
There are myriad ways to analyze any given dataset. But which one trust? In the face of such uncertainty, analysts adopt multiverse analysis: running all reasonable analyses on Yet this is cognitively and technically difficult with existing tools—how does specify execute combinations a dataset?—and often requires discarding workflows. We present multiverse, tool for implementing in R expressive syntax supporting computational notebook Informed by iterative user testing, supports building up...
Abstract 80% of all breast cancers express the estrogen receptor alpha (ERα) and thus are treated with anti-hormonal therapies that directly block ER function (e.g.Tamoxifen) or hormone synthesis (Aromatase Inhibitors). While these initially effective, acquired resistance invariably emerges disease progression ensues. Importantly, majority tumors continue to depend on ERα for growth survival via both ligand-dependent ligand-independent pathways. The emerging evidence can be activated in...
Abstract The majority of breast cancers express estrogen receptor alpha (ERα) and thus are treated with anti-hormonal therapies that directly block ER function (e.g.Tamoxifen) or hormone synthesis (Aromatase Inhibitors). While these initially effective, acquired resistance emerges disease progression ensues. Importantly, the tumors continue to depend on ERα for growth survival via both ligand-dependent ligand-independent pathways. emerging evidence can be activated in absence estrogens point...
The general problem of constructing confidence regions is unsolved in the sense that there no algorithm provides such a region with guaranteed coverage for an arbitrary parameter $ψ\inΨ.$ Moreover, even when exists, it may be absurd either set $Ψ$ or null $ϕ$ reported positive probability. An approach to construction and which avoids absurdity applied here several problems have been discussed recent literature some standard approaches produce regions.
Abstract The majority of breast cancers express and rely on ERα for tumor growth, thus endocrine therapy is the mainstay ER-positive cancer treatment. Despite effectiveness current therapies, many patients relapse with tumors still dependent ER growth via both estrogen-dependent estrogen-independent mechanisms. Acquired mutations in ESR1 were recently identified ligand-binding domain who progressed after aromatase inhibitors tamoxifen. It estimated that more than 20% relapsed acquire...
Abstract The general problem of constructing regions that have a guaranteed coverage probability for an arbitrary parameter interest $$\psi \in \Psi $$ <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"> <mml:mrow> <mml:mi>ψ</mml:mi> <mml:mo>∈</mml:mo> <mml:mi>Ψ</mml:mi> </mml:mrow> </mml:math> is considered. developed are Bayesian in nature and the probabilities can be considered as confidences with respect to model obtained by integrating out nuisance parameters using conditional...
Abstract Greater than 50% of high grade serous ovarian cancers express the estrogen receptor alpha (ERα). This observation, in addition to multiple lines epidemiological and preclinical data, suggests that, similar breast endometrial cancer, signaling may play a role development progression cancer. Unfortunately, unlike therapeutically targeting ERα patients with recurrent cancer typically yields only marginal clinical responses. However, patient selection based solely on expression...
Background: The Coronavirus disease (COVID-19) has been the cause of more than 13,350 deaths in Canada. As a result, nonpharmaceutical interventions (NPIs) have adopted by government officials to mitigate dissemination disease. Quantifying NPI effectiveness is challenging due variability their implementation between geographic regions. Mobility data can help understand role NPIs reducing COVID-19 cases.Methods: used this analysis consists individual level time-series confirmed positive cases...